Patent · US Active

Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith

US10151755B2 · kind B2 · utility

5Cited by
0References
4Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJun 1, 2016
Grant dateDec 11, 2018
Priority date
Expiry dateJun 24, 2036

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/8146
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

The invention relates to biomarker assays based on protein/peptide biomarkers which show a pronounced differential behaviour between healthy and cancerous sample proteomes e.g. by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the protein biomarkers in serum, plasma or blood itself.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.